PubRank

W Paul Bowman

Author PubWeight™ 65.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009 10.54
2 Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009 7.95
3 Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008 5.49
4 Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 2011 4.93
5 Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009 4.20
6 Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010 4.00
7 Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010 3.76
8 Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010 3.66
9 Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011 3.40
10 Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 2009 2.86
11 Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2012 2.09
12 Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 2012 1.90
13 Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 2011 1.88
14 Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst 2013 1.81
15 Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol 2011 1.60
16 Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet 2013 1.45
17 Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 2012 1.30
18 Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2010 1.16
19 Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer 2013 0.98
20 Effect of body mass index on the outcome of children with acute myeloid leukemia. Cancer 2012 0.90
21 Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group. Cytometry B Clin Cytom 2005 0.88
22 Treatment outcome in older patients with childhood acute myeloid leukemia. Cancer 2012 0.86
23 Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatr Blood Cancer 2014 0.77
24 Early Nutrition Intervention Attenuates Weight Gain for Pediatric Acute Lymphoblastic Leukemia Patients in Maintenance Therapy. J Pediatr Hematol Oncol 2017 0.75
25 Correlation of Lipid Profile and Risk of Developing Type 2 Diabetes Mellitus in 10-14 Year Old Children. Cell Physiol Biochem 2016 0.75